investigators – Page 6 – Communicable Diseases Research

Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial

무증상 및 경증 COVID-19 환자에 대한 nelfinavir의 효능 및 안전성: 다기관, 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-282022-09-10
Journal: Trials [Category] SARS, 임상, 치료기술,

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

무작위 시험의 국제 협력 메타 분석에서 COVID-19에서 히드록시클로로퀸과 클로로퀸의 사망률 결과

Meta-Analysis

Published on 2021-04-152022-09-10
Journal: Nature Communications [Category] MERS, SARS, 바이오마커, 임상, 치료법,

[키워드] 95% CI 95% confidence interval all-cause mortality Analysis benefit bioRxiv children Chloroquine CIs clinical clinical trials Comorbidities COVID-19 COVID-19 patient COVID-19 patients COVID-19 research diagnostic Effect Effects eligible Epidemiology Evidence finding Generalizability High dose Hydroxychloroquine hydroxychloroquine/chloroquine include increased mortality International investigated investigator investigators medRxiv Meta-analysis Mortality Odds ratio Odds ratios outcome outpatients Patient patients Potential treatment Pragmatic pregnant women random-effects meta-analyses randomized clinical trial randomized trial RCT RCTs recovery recruitment registry Result survival total sample size Treatment Trial trials viral infection WHO WHO International Clinical Trials Registry Platform
[DOI] 10.1038/s41467-021-22446-z PMC 바로가기 [Article Type] Meta-Analysis

A risk assessment tool for resumption of research activities during the COVID-19 pandemic for field trials in low resource settings

저자원 환경에서 현장 시험을 위해 COVID-19 전염병 동안 연구 활동을 재개하기 위한 위험 평가 도구

Research Article

Published on 2021-04-122022-09-10
Journal: BMC Medical Research Methodology [Category] Fulltext, MERS, 임상,

[키워드] activities activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Air pollution approach assigned benefit biosafety Combination conducted Coronavirus-2 country COVID-19 COVID-19 pandemic Data collection develop environmental health evaluate exposure time framework Government Guidance highest household infection risk integrity investigator investigators Laboratory Local local government measure Measures Non-COVID-19 objective outbreak pandemic participant Participants Pollution PROTECT Protective provided rationale recommendation Registered Research resource respiratory Result risk Risk assessment SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Spread subject supplementary material Transmission dynamics Trial Viral virus
[DOI] 10.1186/s12874-021-01232-x PMC 바로가기 [Article Type] Research Article

Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial

페루의 초기 COVID-19 환자(SAINT-Peru)에서 비인두 PCR을 무효화하기 위해 이버멕틴 대 위약의 효능을 비교하기 위한 무작위 임상 시험(SAINT-Peru): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-092022-09-01
Journal: Trials [Category] MERS, 임상, 진단,

[키워드] 1:1 Administered adverse event allergy Amiodarone Anosmia Antiviral attending physician baseline blinded Blinding block childbearing age clarithromycin clinical clinical and laboratory parameters clinical care clinical trial Cobicistat coin conducted control group correlation cough COVID-19 COVID-19 disease COVID-19 patient COVID-19 pneumonia COVID-19 progression criteria Critical current cyclosporine CYP3A4 daily dose death determine determined by diagnosed diagnostic test Diltiazem dissemination dose drug early treatment Efficacy element Eligible patients emergency services enrolled epidemiologist erythromycin evaluate expected Fever follow-up visits generate hospital Hospitalization IgA IgG IgM IIa immune response immunomodulatory in vivo include inclusion criteria Indinavir Infection Informed consent inhibitor Intervention intestinal investigator investigators involved itraconazole Ivermectin ketoconazole laboratory parameter less list lung magnitude medical staff nasopharyngeal nasopharyngeal specimen Nasopharyngeal swab nasopharyngeal swab PCR nasopharyngeal swabs National negative number objective Older outcome oxygen oxygen saturation Parallel Arm participant Patient patients patients with SARS-CoV-2 PCR PCR cycle Peru Pharmacist phase Placebo placebo group placebo-controlled trial Pneumonia positive positive PCR test positive SARS-CoV-2 PCR pregnancy test pregnant women principal investigator progression proportion protocol quinidine randomization list Randomized Randomized controlled trial Randomly Rapid diagnostic test receive recruited reduce Registered Registration Result risk factor Risk factors Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 RNA SARS-CoV-2 viral load secondary Secondary objectives Seroconversion Seven severe disease severity spironolactone statistician status study population Study protocol supplementary material Symptom symptomatic Symptomatology Symptoms tacrolimus the patient the placebo group the SARS-CoV-2 threshold Treatment treatment group treatment groups treatment initiation Trial Trial registration two group two groups verapamil Viral Viral load virus Warfarin website with COVID-19 women
[DOI] 10.1186/s13063-021-05236-2 PMC 바로가기 [Article Type] Letter

Urgent care center wait times increase for COVID-19 results in August 2020, with rapid testing availability limited

2020년 8월에 COVID-19 결과에 대한 긴급 치료 센터 대기 시간이 증가하고 빠른 테스트 가용성이 제한됨

Research Article

Published on 2021-04-082022-09-10
Journal: BMC health services research [Category] MERS, SARS, 치료기술,

Difficulties in Differentiating Coronaviruses from Subcellular Structures in Human Tissues by Electron Microscopy

전자 현미경으로 인간 조직의 세포 내 구조에서 코로나바이러스를 구별하는 데 어려움

Review

Published on 2021-04-012022-09-10
Journal: Emerging Infectious Diseases [Category] MERS, SARS, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition caused characteristic coated coronavirus coronavirus disease COVID-19 COVID-19 patient cross damage difficulty electron electron microscopy Endoplasmic reticulum Extracellular focus Human investigator investigators less membrane-bound morphologic feature morphologic features multivesicular bodies negative stain nucleocapsid pandemic Particles pathology reported respiratory respiratory infections SARS SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 spike Structure subcellular structures thin sections tissue damage tissues transmission electron microscopy ultrastructure vesicles virus viruses zoonoses
[DOI] 10.3201/eid2704.204337 PMC 바로가기 [Article Type] Review

Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure

SARS-CoV-2 비리온 단백질 및 구조에 대한 비활성화 방법의 영향

Article

Published on 2021-03-262022-09-01
Journal: Viruses [Category] SARS, 진단, 치료기술,

[키워드] Antibody detection assays best biosafety biosafety level Biosafety Level 3 BSL3 comparable conditions conducted coronavirus detectable Effect electron microscopy ELISA Genome heat inactivation impacted inactivated inactivation Incubation Infection investigator investigators less level 3 meet protocol purification reduction Research respiratory resulting risk SARS-CoV-2 severe acute respiratory syndrome Coronavirus Severe Acute Respiratory Syndrome Coronavirus -2 Structure Treatment ultraviolet ultraviolet irradiation UV inactivation Viral Viral protein Viral proteins Viral RNA viral RNA quantification viral stocks virion virions virus western blot working
[DOI] 10.3390/v13040562 PMC 바로가기 [Article Type] Article

The Importance and Challenges of Identifying SARS-CoV-2 Reinfections

SARS-CoV-2 재감염 식별의 중요성과 과제

Review

Published on 2021-03-192022-09-11
Journal: Journal of Clinical Microbiology [Category] SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition challenge Community consequence coronavirus Course COVID-19 described determinants different time point Establishing explain Frequency genomic data help identifying IgG immune protection immune response Immunity Immunoglobulin Importance Infection initial investigators key factor Laboratory less logistics occurred pandemic Patient positive Primary infection Prospective Study question raised raising Reinfection report SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity strength Surveillance Viral genome sequencing viral immunity virus was performed
[DOI] 10.1128/JCM.02769-20 PMC 바로가기 [Article Type] Review

Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial

COVID-19(FLARE) 외래 환자의 조기 항바이러스 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-03-082022-09-01
Journal: Trials [Category] SARS, 임상, 진단, 치료기술, 치료제,

[키워드] 24 hours 48 hour 48 hours absence admitted to ICU aetiology age ALT Analysis Anosmia anticipated antiviral therapy Antiviral treatment antivirals Appendix Arm arrhythmia AST Asthma Asymptomatic Autoimmune blinded to treatment Blinding blood sample BMI Breastfeeding childbearing potential Cholangitis chronic chronic hepatitis Chronic kidney disease chronic liver disease chronic respiratory disease cirrhosis clinical condition collected combination therapy Comorbidity concealed Concomitant concomitant medications conducted COPD coryza cough COVID-19 COVID-19 disease COVID-19 vaccine criteria current Date Day decrease defined Deleterious detectable diabetes died disease dissemination dose double-blind Duration early treatment effective EGFR element enrolled enrolment Ethnicity examined exclusion criteria factorial design Favipiravir female female participant Fever followed by Free Gender headache heart disease Hepatitis hepatotoxicity HIV infection hospital hospitalisation hypersensitivity hypertension in viral include inclusion criteria ingredient investigator investigators Ischaemic heart disease Kidney disease liver Liver disease London Lopinavir Lopinavir/ritonavir malaise male participant male participants measure medication Mutation myalgia Myocardial infarction no symptom non-hospitalised not limited number obesity objective observational studies observational study oral outcome Outpatient outpatients participant Participants partner percentage pharmacokinetic phase IIa Placebo placebo-controlled placebo-controlled trial positive presence or absence Primary outcome Proportion of participant Protease inhibitor protocol randomised randomised controlled trial Rate Registered Registration respiratory Respiratory disease risk Ritonavir Safety Saliva saliva samples Sample size SARS-CoV-2 secondary Secondary outcomes Shortness of breath smoker smoking smoking status Stage status steatohepatitis Stool Study protocol supplementary material Symptom symptom onset symptomatic tested therapy Toxicity Treatment treatment allocation Trial trial medication Trial registration undetectable United Kingdom upper respiratory tract vaccine trial valvular valvular heart disease Viral Viral load website with COVID-19
[DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter

Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial

ARDS 및 COVID-19 환자에서 덱사메타손의 효과 – 전향적, 다기관, 공개 라벨, 병렬 그룹, 무작위 대조 시험(REMED 시험): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-03-012022-09-10
Journal: Trials [Category] SARS, 임상, 치료기술,

[키워드] (C-reactive protein 24 hour 24 hours administration adrenal gland Adult patients Adverse adverse events age alcohol allergy allocation Antigen ARDS ARDS patients ARMS assumed Barthel Index benzyl alcohol Berlin Berlin criteria Blinding Block randomisation Brazil Breastfeeding C-reactive protein calculated can be used Cardiac arrest Care carried case report form CCI Charlson Comorbidity Index Chemotherapy clinical Comorbidity comparator completion condition conducted consequence Contraception control group Corticosteroid Corticosteroids COVID-19 COVID-19 ARDS patient criteria CRP current Czech Republic Day decision defined detect Dexamethasone dexamethasone 6 mg diagnosed dissemination dose doses Dynamics eCRF Effect Effectiveness Efficacy and safety electronic case report form element eligible Endpoint enrolled enrolment EudraCT evaluate event expected exploratory Factor followed by French gastrointestinal bleeding HFNC hospital hospital discharge Hospital stay hypersensitivity Hypothesis ICU ICU admission ICUs Identifier Immunosuppression immunosuppressive drug immunosuppressive drugs Independence independent independent of Infection infections Inflammatory infusion intensive care unit intensive care units Intervention intervention group intractable intravenously intubate intubation investigational medicinal product investigator investigators Laboratory life malignancy marker mechanical ventilation medical history moderate moderate to severe Mortality nasal nasal cannula number objective observational study once daily Open-label open-label trial outcome oxygen Oxygen therapy PaO parallel-group participant Participation Patient patients with ARDS patients with moderate performed power power of 80% Pragmatic Pregnancy present primary efficacy endpoint primary endpoint protocol Quality of life randomisation randomised randomised controlled trial receive recruitment Registered routine clinical practice RT-PCR Sample size scale secondary Secondary endpoints Septic shock sequence severe ARDS sexual abstinence solution Standard deviation statistical analysis statistician status Stratification stratified Study protocol superinfection supplementary material systemic systemic corticosteroids thrombotic Thrombotic complications title Treatment treatment arm Trial Trial registration two-sided type I type I error university hospital Ventilation ventilator-free day Ventilator-free days Version VFD website WHO
[DOI] 10.1186/s13063-021-05116-9 PMC 바로가기 [Article Type] Letter